Sign In
Buy EWTX
$43.52
-0.90 (-2.03%)
At Close: Aug 07, 2026
Why Edgewise Therapeutics Stock Crushed the Market on Monday
08:05pm, Monday, 09'th Feb 2026
One of the more bullish analysts tracking the company reiterated her enthusiastic buy recommendation on the biotech. She has flagged it as one of her firm's best stock ideas for this year.
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
08:00am, Thursday, 05'th Feb 2026
BOULDER, Colo., Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
08:00am, Monday, 02'nd Feb 2026
BOULDER, Colo., Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutic
Badreddin Edris Sells 115,471 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock
05:06am, Sunday, 25'th Jan 2026
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) Director Badreddin Edris sold 115,471 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an averag
Campbell & CO Investment Adviser LLC Lowers Holdings in Edgewise Therapeutics, Inc. $EWTX
03:44am, Sunday, 25'th Jan 2026
Campbell and CO Investment Adviser LLC trimmed its stake in Edgewise Therapeutics, Inc. (NASDAQ: EWTX) by 90.2% during the undefined quarter, according to its most recent disclosure with the Securitie
Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:05pm, Tuesday, 13'th Jan 2026
Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
08:00am, Tuesday, 13'th Jan 2026
- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions - - Presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Ja
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
08:00am, Tuesday, 06'th Jan 2026
BOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D.
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
08:00am, Monday, 05'th Jan 2026
BOULDER, Colo., Jan. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits
05:33pm, Monday, 29'th Dec 2025
California-based Foresite Capital Management VI sold 585,000 shares of Edgewise Therapeutics in the third quarter. The overall position value fell by about $7.67 million from the previous period.
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst
02:55pm, Monday, 29'th Dec 2025
Edgewise Therapeutics, Inc. maintains a Buy rating, driven by favorable interim 12-week safety data for EDG-7500 in phase 2 CIRRUS-HCM and multiple 2026 catalysts. EDG-7500 demonstrated strong tolerab
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 5.2% – Time to Sell?
02:36am, Sunday, 28'th Dec 2025
Shares of Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) dropped 5.2% during mid-day trading on Friday. The company traded as low as $26.12 and last traded at $25.88. Approximately 198,7
Why Edgewise Therapeutics Stock Rocked the Market Today
06:00pm, Wednesday, 24'th Dec 2025
The biotech gifted quite a holiday present to its investors. An investigational drug continues to show significant promise.
BOULDER, Colo., Dec. 24, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel ora
Edgewise Therapeutics (NASDAQ:EWTX) Shares Up 11.9% – Still a Buy?
03:32am, Sunday, 21'st Dec 2025
Edgewise Therapeutics, Inc. (NASDAQ: EWTX - Get Free Report) shot up 11.9% during trading on Friday. The stock traded as high as $23.55 and last traded at $23.6650. 566,092 shares were traded during m
